According to a new study, patients with atopic dermatitis (AD) are more likely to achieve mild disease severity when treated with dupilumab and adjuvant tacrolimus as opposed to dupilumab alone.
top of page
bottom of page
According to a new study, patients with atopic dermatitis (AD) are more likely to achieve mild disease severity when treated with dupilumab and adjuvant tacrolimus as opposed to dupilumab alone.
Comments